... and lack of toxicity require confirmation. Given the initial integration of HIV genetic information into host genome at the outset of infection, however, it is difficult to envisage a genuinely curative therapy for HIV infection; but in view of the ...

... use a combined modality approach that includes 1) antiretroviral therapy, 2) ... with asymptomatic HIV infection. A virus vaccine may be more difficult ...

... all stages of HIV disease. Partic- ularly as antiretroviral drugs and opportunistic in- fection prophylaxis in early HIV disease are found to be effective, physicians should insist that access to these therapies not be impeded by public or pri- vate ...

... hospitalization. Even with the advent of new, expensive therapies for HIV and related illnesses in the ’80’s, estimated annual cost per case of AIDS dropped from an initial $147,000 to $25-30,000. While this ...

... with placebo, but medical intervention in addition to antiretroviral therapy must ... the initial episode. Prophylaxis is categorized as secondary if the ...

... risks associated with trimethoprim-sulfamethoxazole or aerosolized pentamidine ~ ... immunocompromised HIV-infected pregnant women (i.e., those with CD4+ ...

... distribution system, March-September, 1987. J Acq Immun REFERENCES Def Synd 1990;3:460. _ Des Jarlais DC, Friedman SR, Stoneburner RL. HIV infec- 1. Gail MH, Roseberg PS, Goedert JJ. Therapy may explain tion and intravenous drug use: critical ...

... pmmary prophylaxis of PCP during the asymptomatic period. Initial studies have ... care for asymptomatic HIV disease has therefore already be- gun, and we ...

... 95 children with symptomatic (CDC class P-2) HIV infection enrolled in a phase I-II study to assess the safety and antiretroviral activity of ddl, 5 developed peripheral atrophy of the retinal pigment epithelium during ddl therapy. The two children with the most severe retinal ...